- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00530920
Tipranavir/Ritonavir Low Dose Pharmacokinetics in Treatment Naive Patients
A Multicenter, Randomized, Open Label, Clinical Trial to Evaluate Three Doses of Tipranavir Boosted With Ritonavir (500 mg/200 mg qd, 250 mg/100 mg Bid and 500 mg/100 mg Bid) by Assessing the Steady-state Pharmacokinetics and Short-term Efficacy and Safety in HIV-1 Positive Treatment naïve Patients
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
-
Berlin, Duitsland
- 1182.107.49002 Boehringer Ingelheim Investigational Site
-
Berlin, Duitsland
- 1182.107.49004 Boehringer Ingelheim Investigational Site
-
Frankfurt/Main, Duitsland
- 1182.107.49003 Boehringer Ingelheim Investigational Site
-
München, Duitsland
- 1182.107.49001 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Antella (fi), Italië
- 1182.107.39001 Boehringer Ingelheim Investigational Site
-
Bari, Italië
- 1182.107.39009 Boehringer Ingelheim Investigational Site
-
Ferrara, Italië
- 1182.107.39007 Boehringer Ingelheim Investigational Site
-
Palermo, Italië
- 1182.107.39011 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Barcelona, Spanje
- 1182.107.34001 Boehringer Ingelheim Investigational Site
-
Barcelona, Spanje
- 1182.107.34002 Boehringer Ingelheim Investigational Site
-
L'Hospitalet de Llobregat, Spanje
- 1182.107.34003 Boehringer Ingelheim Investigational Site
-
Madrid, Spanje
- 1182.107.34004 Boehringer Ingelheim Investigational Site
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Signed informed consent in accordance with GCP and local regulatory requirements prior to trial participation.
- HIV-1 infected men and non-pregnant women who are treatment naïve, with positive serology (EIA) confirmed by Western blot.
- Age > 18 and < 65 years.
- CD4 > 200 cells/mm3
- Viral load (HIV-1 mRNA viral load) > 5,000 copies/mL.
- Ability to swallow multiple large capsules without difficulty.
- Acceptable laboratory values that indicate adequate baseline organ function at screening visit.
- Laboratory values are considered to be acceptable if the severity of any parameter is = < Grade 2, based on the DAIDS/ACTG Grading Scale (see Appendix 10.2).
- Acceptable medical history, physical examination, and 12-lead ECG at screening
Willingness to abstain from the following starting 2 weeks prior to administration of any study medication and up until the end of the study:
o Grapefruit or grapefruit juice, Seville oranges, St. John's Wort, and Milk Thistle.
- Willingness to abstain from alcohol 3 days prior to administration of any study medication up to the end of the study.
Willingness to abstain from the following starting 3 days prior to PK sampling:
o Garlic supplements and methylxanthine containing foods or drinks (including coffee, tea, cola, energy drinks, chocolate, etc.).
- Willingness to abstain from over-the-counter herbal medications for the duration of the study.
- Willingness to abstain from any over the counter medication 7 days prior to administration of any study medication (including vitamins, minerals, dietary supplements and antacids) during the study until completion of the post study assessments.
Exclusion Criteria:
Female patients of reproductive potential who:
- Have positive serum pregnancy test.
- Have not been using a barrier method of contraception for at least 3 months prior to participation in the study.
- Are not willing to use a reliable method of barrier contraception (such as diaphragm with spermicidal cream/jelly or condoms with spermicidal foam), during and 60 days after completion/termination of the trial.
- Are breast-feeding.
- Suspected or documented seroconversion within last 6 months
- Participation in another trial with an investigational medicine within 2 months prior to Day 0 of this study.
- Use of any pharmacological contraceptive (including oral, patch or injectable contraceptives) within 1 month prior to Day 0 and for the duration of the study.
- Use of hormone replacement therapy within 1 month prior to Day 0 and anytime during the study.
- History of acute illness within 30 days prior to Day 0.
- Have evidence of active or acute HBV or HCV.
- Alcohol or substance abuse within 1 year prior to screening or during the study.
- Patients with a history of any illness or allergy that, in the opinion of the investigator, might confound the results of the study or pose additional risk in administering TPV.
- Patients who have taken (within 7 days prior to Day 0) any over-the-counter or prescription medication that, in the opinion of the investigator in consultation with the BI clinical monitor, might interfere with absorption, distribution, or metabolism of the study medications.
- Known hypersensitivity to any ingredients of the test drug.
- Inability to adhere to the protocol.
- Genotypic resistance to tipranavir (defined as a TPV mutation score > 4).
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Interventioneel model: Parallelle opdracht
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Viral Load (log10 Copies/mL) Change From Baseline (Last Observation Carried Forward (LOCF))
Tijdsspanne: Baseline (Day 0) to Final (Day 14)
|
Baseline (Day 0) to Final (Day 14)
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Apparent Oral Clearance I(Cl/F) of Tipranavir
Tijdsspanne: Final (Day 14)
|
Tipranavir pharmacokinetics - Clearance (CL) is defined as the dose of a drug divided by the area-under-the-concentration-time curve (AUC), ie.
CL = Dose / AUC.
For extravascu-lar models the fraction of dose absorbed cannot be estimated, therefore "clear-ance" for these models is actually Cl/F where F is the fraction of the drug dose which is absorbed.
|
Final (Day 14)
|
Area Under the Curve(AUC) of Tipranavir 24 h for Once Daily (QD) and AUC 12 h for Twice Daily (BID)
Tijdsspanne: Final (Day 13 for QD, Day 14 for BID)
|
Tipranavir (TPV) pharmacokinetics
|
Final (Day 13 for QD, Day 14 for BID)
|
Concentration-24 Hour (hr) Post Dose of Tipranavir - (Cp 24 h for QD and 12 hr Post Dose (CP 12h) for BID
Tijdsspanne: Final (Day 13 for QD, Day 14 for BID)
|
TPV pharmacokinetics
|
Final (Day 13 for QD, Day 14 for BID)
|
Trough Concentration (Cmin) of Tipranavir
Tijdsspanne: Final (Day 13 for QD, Day 14 for BID)
|
TPV pharmacokinetics
|
Final (Day 13 for QD, Day 14 for BID)
|
Maximum Concentration (Cmax) of Tipranavir
Tijdsspanne: Final (Day 13 for QD, Day 14 for BID)
|
TPV pharmacokinetics
|
Final (Day 13 for QD, Day 14 for BID)
|
Volume of Distribution (V/F) of Tipranavir
Tijdsspanne: Final (Day 14)
|
Tipranavir pharmacokinetics
|
Final (Day 14)
|
Terminal Half-Life (t1/2) of Tipranavir
Tijdsspanne: Final (Day 14)
|
Tipranavir pharmacokinetics
|
Final (Day 14)
|
Time to Cmax (Tmax) of Tipranavir
Tijdsspanne: Final (Day 14)
|
Tipranavir pharmacokinetics
|
Final (Day 14)
|
AUC 24 of Ritonavir for QD and AUC 12 of Ritonavir for BID
Tijdsspanne: Final (Day 13 for QD, Day 14 for BID)
|
Ritonavir pharmacokinetics
|
Final (Day 13 for QD, Day 14 for BID)
|
Cp 24 h of Ritonavir for QD and CP 12 h of Ritonavir for BID
Tijdsspanne: Final (Day 13 for QD, Day 14 for BID)
|
Ritonavir pharmacokinetics
|
Final (Day 13 for QD, Day 14 for BID)
|
Apparent Oral Clearance I(Cl/F) of Ritonavir
Tijdsspanne: Final (Day 13 for QD, Day 14 for BID)
|
Ritonavir pharmacokinetics
|
Final (Day 13 for QD, Day 14 for BID)
|
Volume of Distribution (V/F) of Ritonavir
Tijdsspanne: Final (Day 14)
|
Ritonavir pharmacokinetics
|
Final (Day 14)
|
Terminal Half-Life (t1/2) of Ritonavir
Tijdsspanne: Final (Day 14)
|
Ritonavir pharmacokinetics
|
Final (Day 14)
|
Tmax of Ritonavir
Tijdsspanne: Final (Day 14)
|
Ritonavir pharmacokinetics
|
Final (Day 14)
|
Cmax of Ritonavir
Tijdsspanne: Visits baseline, 5, 7, 9 and 13 or 14
|
Ritonavir pharmacokinetics
|
Visits baseline, 5, 7, 9 and 13 or 14
|
Clinical Abnormal Findings in Laboratory and Physical Examination
Tijdsspanne: Screening through the end of the study (14 days)
|
Screening through the end of the study (14 days)
|
Medewerkers en onderzoekers
Sponsor
Publicaties en nuttige links
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- RNA-virusinfecties
- Virusziekten
- Infecties
- Door bloed overgedragen infecties
- Overdraagbare ziekten
- Seksueel overdraagbare aandoeningen, viraal
- Seksueel overdraagbare aandoeningen
- Lentivirus-infecties
- Retroviridae-infecties
- Immunologische deficiëntie syndromen
- Ziekten van het immuunsysteem
- HIV-infecties
- Moleculaire mechanismen van farmacologische werking
- Anti-infectieuze middelen
- Antivirale middelen
- Enzymremmers
- Anti-hiv-middelen
- Antiretrovirale middelen
- Proteaseremmers
- Cytochroom P-450 CYP3A-remmers
- Cytochroom P-450 enzymremmers
- HIV-proteaseremmers
- Virale proteaseremmers
- Ritonavir
- Tipranavir
Andere studie-ID-nummers
- 1182.107
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op HIV-infecties
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthWervingHiv | HIV-testen | Hiv-koppeling naar zorg | HIV-behandelingVerenigde Staten
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement; Centre Pasteur du Cameroun en andere medewerkersOnbekendHiv | HIV-niet-geïnfecteerde kinderen | Kinderen blootgesteld aan HIVKameroen
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationVoltooidPartner hiv-testen | HIV-counseling voor koppels | Paar communicatie | HIV-incidentieKameroen, Dominicaanse Republiek, Georgië, Indië
-
University of MinnesotaIngetrokkenHIV-infecties | Hiv/aids | Hiv | AIDS | Aids/Hiv probleem | AIDS en infectiesVerenigde Staten
-
Erasmus Medical CenterNog niet aan het wervenHIV-infecties | Hiv | HIV-1-infectie | HIV I-infectieNederland
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London; University... en andere medewerkersWervingHiv | HIV-testen | Koppeling aan zorgZuid-Afrika
-
CDC FoundationGilead SciencesOnbekendHIV Pre-expositie profylaxe | Hiv-chemoprofylaxeVerenigde Staten
-
University of Maryland, BaltimoreIngetrokkenHiv | Niertransplantatie | HIV-reservoir | CCR5Verenigde Staten
-
Hospital Clinic of BarcelonaVoltooidIntegrase-remmers, HIV; HIV PROTEASE INHIBSpanje
-
Helios SaludViiV HealthcareOnbekendHiv | HIV-1-infectieArgentinië
Klinische onderzoeken op tipranavir
-
Boehringer IngelheimVoltooid
-
Boehringer IngelheimVoltooidHIV-infectiesVerenigde Staten, Puerto Rico
-
Boehringer IngelheimVoltooid
-
Boehringer IngelheimVoltooid
-
Germans Trias i Pujol HospitalFundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción...Voltooid
-
Boehringer IngelheimBeëindigdHIV-infectiesVerenigde Staten, Argentinië, Brazilië, Frankrijk, Duitsland, Italië, Spanje